Lexicon Pharmaceuticals shares surge 18.70% after-hours after FDA clears pilavapadin for Phase 3 trials without additional studies.

Lexicon Pharmaceuticals surged 18.7% in after-hours trading following the announcement of a successful End-of-Phase 2 meeting with the FDA for pilavapadin, a potential treatment for diabetic peripheral neuropathic pain. The FDA confirmed no objections to advancing the drug into Phase 3 trials, which will involve two placebo-controlled studies evaluating the 10 mg daily dose. This regulatory endorsement eliminates unanticipated hurdles, accelerating the path toward potential approval and positioning pilavapadin as the first non-opioid therapy for this indication in over two decades. The news directly aligns with the stock’s upward movement, reflecting investor optimism about Lexicon’s ability to de-risk its pipeline and advance a novel treatment addressing a significant unmet medical need.